{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=67",
    "query": {
      "condition": "Phase II",
      "page": 67
    },
    "page_size": 10
  },
  "pagination": {
    "page": 67,
    "page_size": 10,
    "total_count": 21412,
    "total_pages": 2142,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=68&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=66&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T23:51:46.160Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06259981",
      "title": "A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "GLY-200",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glyscend, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 75,
      "start_date": "2024-05-20",
      "completion_date": "2024-10-23",
      "has_results": false,
      "last_update_posted_date": "2025-01-23",
      "last_synced_at": "2026-11-15T23:51:46.160Z",
      "location_count": 5,
      "location_summary": "Clearwater, Florida • Ocoee, Florida • Marrero, Louisiana + 2 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Ocoee",
          "state": "Florida"
        },
        {
          "city": "Marrero",
          "state": "Louisiana"
        },
        {
          "city": "Butte",
          "state": "Montana"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06259981"
    },
    {
      "nct_id": "NCT04163419",
      "title": "Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schwannomatosis",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Tanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-04-30",
      "completion_date": "2024-09-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-11-15T23:51:46.160Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04163419"
    },
    {
      "nct_id": "NCT02649530",
      "title": "A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma, Head And Neck"
      ],
      "interventions": [
        {
          "name": "WNT974",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-09-30",
      "last_synced_at": "2026-11-15T23:51:46.160Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02649530"
    },
    {
      "nct_id": "NCT05556265",
      "title": "A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "Deucravacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 94,
      "start_date": "2022-11-08",
      "completion_date": "2024-05-16",
      "has_results": true,
      "last_update_posted_date": "2025-05-31",
      "last_synced_at": "2026-11-15T23:51:46.160Z",
      "location_count": 12,
      "location_summary": "Santa Monica, California • New Haven, Connecticut • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Clinton Township",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05556265"
    },
    {
      "nct_id": "NCT01828021",
      "title": "Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Margetuximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2013-03",
      "completion_date": "2017-04-14",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-11-15T23:51:46.160Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Stanford, California • Plantation, Florida + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01828021"
    },
    {
      "nct_id": "NCT02603328",
      "title": "Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cerebral Cavernous Malformation"
      ],
      "interventions": [
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2018-07-17",
      "completion_date": "2025-03-31",
      "has_results": true,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-11-15T23:51:46.160Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02603328"
    },
    {
      "nct_id": "NCT04995081",
      "title": "Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Biological/Vaccine: Allogeneic HB-adMSCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Hope Biosciences Research Foundation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "45 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-07-16",
      "completion_date": "2025-10-03",
      "has_results": true,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-11-15T23:51:46.160Z",
      "location_count": 1,
      "location_summary": "Sugar Land, Texas",
      "locations": [
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04995081"
    },
    {
      "nct_id": "NCT03963739",
      "title": "Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Stage I Prostate Cancer",
        "Stage II Prostate Cancer",
        "Stage III Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Interview",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 255,
      "start_date": "2019-07-19",
      "completion_date": "2025-03-25",
      "has_results": false,
      "last_update_posted_date": "2025-07-16",
      "last_synced_at": "2026-11-15T23:51:46.160Z",
      "location_count": 325,
      "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Hot Springs, Arkansas + 204 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Arroyo Grande",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03963739"
    },
    {
      "nct_id": "NCT03468075",
      "title": "Gemcitabine Plus Ascorbate for Sarcoma in Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma",
        "Soft Tissue Sarcoma",
        "Unresectable Soft Tissue Sarcoma",
        "Metastatic Bone Tumor",
        "Bone Sarcoma"
      ],
      "interventions": [
        {
          "name": "Ascorbate",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mohammed Milhem, MBBS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2018-07-11",
      "completion_date": "2020-10-19",
      "has_results": true,
      "last_update_posted_date": "2020-12-10",
      "last_synced_at": "2026-11-15T23:51:46.160Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03468075"
    },
    {
      "nct_id": "NCT03172975",
      "title": "Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hookworm Infections"
      ],
      "interventions": [
        {
          "name": "Na-GST-1/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Na-GST-1/Alhydrogel + CPG 10104",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Na-GST-1/Alhydrogel + GLA-AF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Albendazole",
          "type": "DRUG"
        },
        {
          "name": "Necator americanus Larval Inoculum",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 39,
      "start_date": "2018-03-01",
      "completion_date": "2025-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-11-15T23:51:46.160Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03172975"
    }
  ]
}